<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal CancerChristos S. Karapetis, John Zalcberg, Shirin Khambata‐Ford et al.|New England Journal of Medicine|2008Cited by 3.6k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon CancerChristine Ribic, Steven Gallinger, Malcolm J. Moore et al.|New England Journal of Medicine|2003Cited by 2.1k
Cetuximab for the Treatment of Colorectal CancerDerek J. Jonker, Malcolm J. Moore, Chris J. O’Callaghan et al.|New England Journal of Medicine|2007Cited by 1.8k
Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized TrialsEmmanuel Mitry, Philippe Rougier, Anthony Fields et al.|Journal of Clinical Oncology|2008Cited by 582
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17Stephanie Yasmin Brule, Rachel Goodwin, Derek J. Jonker et al.|European Journal of Cancer|2015Cited by 337